

PCT


WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : A61L 27/00, 2/16, B65B 55/12		A1	(11) International Publication Number: WO 94/23770 (43) International Publication Date: 27 October 1994 (27.10.94)
(21) International Application Number: PCT/FI94/00136 (22) International Filing Date: 12 April 1994 (12.04.94) (30) Priority Data: 931657 14 April 1993 (14.04.93) FI (71) Applicant (for all designated States except US): LEIRAS OY [FI/FI]; PL 415, FIN-20101 Turku (FI). (72) Inventor; and (75) Inventor/Applicant (for US only): LEHTINEN, Risto, Tapani [FI/FI]; Kreiviläntie 24, FIN-21330 Paattinen (FI). (74) Agent: TURUN PATENTTIITOIMISTO OY; P.O. Box 99, FIN-20521 Turku (FI).		(81) Designated States: AT, AU, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KP, KR, KZ, LK, LU, LV, NL, NO, NZ, PL, PT, RO, RU, SE, SI, SK, UA, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published With international search report.	

(54) Title: A METHOD OF TREATING ENDO-OSTEAL MATERIALS



(I)

(57) Abstract

A packaged endo-osteal material to be used in surgery for sterile and biocompatibility promoting storage comprising the endo-osteal material treated with a solution of a bisphosphonate of formula (I) wherein X is H, OH, Cl, F or a methyl group and Y is Cl, OH, $-(\text{CH}_2)_2-\text{N}(\text{CH}_3)-(\text{CH}_2)_4-\text{CH}_3$, $-(\text{CH}_2)_n-\text{CH}_3$ or $-(\text{CH}_2)_n-\text{NH}_2$, where n is zero or an integer being 1 to 8, $-\text{NHZ}$, where Z is pyridinyl or cycloheptyl, SZ' , where Z' is pyridinyl or chlorosubstituted phenyl or Y is a pyridinylsubstituted lower alkyl chain; or a non-toxic, pharmaceutically acceptable salt or ester thereof dissolved in an appropriate solvent.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

WO 94/23770

PCT/FI94/00136

1

A METHOD OF TREATING ENDO-OSTEAL MATERIALS

This invention relates to the use of bisphosphonates for the treatment of endo-osteal materials including implants to be used in surgery before their introduction into the human body. The invention concerns particularly the
5 addition of a certain amount of a bisphosphonate to the sterile preservation medium for the endo-osteal materials.

In recent years intensive studies have been made on artificial endo-osteal materials, especially implants, to be introduced in the human body such as artificial joints,
10 fixation plates in skeleton, hips and dental implants. Substantial efforts have been made with respect to materials which give high mechanical strength as well as good biological affinity.

Surgical techniques involving the use of endo-osteal
15 prostheses including implants (screw implants, blade implants, pin implants etc) into bone tissue are extensively used in orthopaedic and dental surgery as a result of the progress made in somatological engineering.

Endo-osteal prostheses can roughly be divided into two
20 groups: those comprising a metallic substrate on the one hand and ceramics and glass-ceramics (bioceramics) on the other hand. Metallic prostheses possess excellent strength properties but rather poor biocompatibility. Titan and its alloys are the most frequently used metallic prostheses in
25 both orthopaedic and dental surgery. In order to enhance the osseointegration and bone bonding process the metallic substrate is normally plasma-spray coated e.g. with apatite or hydroxyapatite to promote the bone bonding process. As examples of endo-osteal orthopaedic prostheses can
30 mentioned Tricon-M and Allopro knee prostheses, Ortholoc tibial prosthesis and Monk, DF-80 and Authopor hip prostheses. Among the frequently used metal substrate implants in the dental field can be mentioned pure titanium

WO 94/23770

PCT/FI94/00136

2

- implants (Nobelpharma, Swede-Vent^R, IMZ). Among coated metallic substrate implant can be mentioned Bonefit^R, a titanium substrate with titanium plasma coating; Steri-Oss^R, a hydroxyapatite-coated metal alloy substrate and
- 5 Calcitec, a hydroxyapatite coated titanium substrate. The ceramic implants are e.g. based on polycrystalline aluminium oxide, Al₂O₃ (Frialit). Glass-ceramics and bioceramics include various compositions of glasses, ceramics and glass-ceramics having ability to bond to bone.
- 10 Endo-osteal materials to be introduced in the human body must be preserved strictly under sterile conditions before use. The preservation can take place under dry conditions or in a sterile solution. All the dental implants used are packed in steril glass syringes. These syringes are either
- 15 empty or contain fisiologic saline solution. Dental implants are normally packaged in small ampouls in some milliliters of sterile sodium chloride solution. The hip prosthesis are packed in sterile containers, all parts in their separate containers without any liquid.
- 20 The preservation of the prostheses and implants before their use is not just a problem relating to sterility. It is known that the biocompatibility of an implant is highly associated with the surface property of the material. It is therefore of great importance that the surface layer is
- 25 carefully controlled and specified at atom level. Two implants initially manufactured from the same material can acquire completely different bioactivity properties depending on how the material is treated. Sterilization can for example vary between two similar implants and thus
- 30 result in totally different biocompatibility for the two similar implants. The problem relating to the risk of contamination of the surface of the implant resulting in inactivation of the implant surface has been realized, and suggestions to overcome the problem have been made. US
- 35 patent 4,712,681 describes a method of packaging artificial implants in sterile and contamination-free manner according

WO 94/23770

PCT/FI94/00136

3

to which the implant is packaged in an inner capsule made of the same material as the implant itself. US 4,763,788 suggests a rather similar solution of the contamination problem; it represents a modification of the double capsule
5 system presented in US 4,712,681.

The sensitivity of the implant surface to particles in the surrounding has thus been regarded as a difficulty to be overcome.

This invention is based on the idea to take advantage of
10 the sensitivity phenomenon and bring the surface of the endo-osteal material in close contact with agents having a positive influence on the biocompatibility of the endo-osteal material. This is practically carried out by adding a biocompatibility promoting agent to a solution in which
15 the endo-osteal material is going to be preserved before its use.

According to one aspect of the invention an effective amount of a bisphosphonate is added to the solution to be used for the preservation of endo-osteal materials such as
20 artificial joints, hip prostheses, fixation plates, dental and other implants. The use of endo-osteal prostheses having been stored in this manner optionally in combination with a systemic bisphosphonate therapy is strongly believed to result in a much lower failure rate
25 compared to the situation where no bisphosphonate is added to the preservation solution for the endo-osteal prosthesis.

Bisphosphonates are synthetic organic compounds structurally related to pyrophosphate in that the pyrophosphate P-O-P-bond is replaced by a P-C-P-bond. In
30 contrast to pyrophosphate, bisphosphonates are resistant to enzymatic hydrolysis in osseous tissue. The bisphosphonates are potent inhibitors of bone resorption and they have been successfully used in the treatment of hypercalcemia caused by various reasons. A great number of bisphosphonates have

WO 94/23770

PCT/FI94/00136

4

been studied, but only clodronate, etidronate and pamidronate have reached wider clinical use.

The main effect of the bisphosphonates is their ability to inhibit bone resorption, but contrary to the effect on mineralization, the mechanism involved is cellular (Fleisch H, Drugs 1991; 42: 919-44). These different effects vary greatly according to the structure of the individual bisphosphonate compound. The half-life of circulating bisphosphonates is very short, in the order of minutes to hours. Of a given dose, 20 to 50 % is taken up by the skeleton, the rest being excreted in the urine. The half-life in bone is far longer and depends upon the turnover rate of the skeleton itself.

A review (Mian M et al., Int J Clin Pharmacol Res. 1991; 11: 107-14) of 126 publications on clinical studies concerning the use of clodronate in the therapy of bone disease, involving 1930 patients, in order to evaluate the tolerability and the effects following short- and long-term administration of this drug, indicates that clodronate therapy does not have any clinically significant side-effects and confirm its tolerability and safety.

Of the many compounds belonging to the bisphosphonate family, clodronate has been widely used in hypercalcemia and osteolysis of malignancy (Bonjour J P and Rizzoli R, Calcif Tissue Int 1990; 46 Suppl: 20-25). All published reports indicate that clodronate can normalize plasma calcium in the majority of hypercalcemic, rehydrated cancer patients in whom increased bone resorption is the prevailing disturbed calcium flux (Fleisch H, Drugs 1991; 42: 919-44).

Various phosphonate compounds are also reported in the patent literature as being useful in the treatment of anomalous mobilization and deposition of calcium phosphate salts (bone mineral) in mammals. Reference is made to US

WO 94/23770

PCT/FI94/00136

5

patents 3,678,164; 3,662,066; 3,553,314; 3,553,315;
3,584,124; 3,584,125 and 3,641,246. US 3,683,080 discloses
the use of clodronate and various other phosphonates for
the treatment of anomalous calcification involving soft
5 tissues and arthritic conditions. US 4,234,645 discloses
clodronate as useful in the treatment of various collagen
diseases.

As discussed above, bisphosphonates are well documented
10 with respect to their ability to inhibit bone resorption in
connection with various diseases. The use of these
compounds to promote bone tissue formation subsequent to
surgical operations relating to endo-osteal prosthesis such
as hip prostheses, plates used in internal rigid fixation
15 and various kinds of implantations; osteomyelitis after
decorticalization of necrotics from the mandible or bone
transplantations has, however, never been suggested.
Particularly in dental implantation surgery, patients with
severe atrophy of the mandibular alveolar process are
20 difficult to treat by conventional implant techniques. At
the abutment connection operation mobile fixtures are found
frequently. About half of the number of recorded failures
occurred under the healing period (Adell R et al., Int J
Oral & Maxillofac Surg 1990, 5: 347-359). Autogenous bone
25 grafts used for severely resorbed ridge augmentation
usually resorb to a considerable extent (Baker R D et al.,
J Oral Surg 1970; 37: 486-89).

The effect of clodronate on hydroxyapatite has been
30 extensively studied. Although the effect of clodronate on
hydroxyapatite is well documented, the use of clodronate
or other bisphosphonates to preserve hydroxyapatite coated
or otherwise coated endo-osteal prostheses including
implants has never been suggested. Neither has been
35 suggested the use of bisphosphonates to activate the
uncoated metal surface of such prostheses or implants.


The present invention relates to a method of treating endo-

WO 94/23770

PCT/FL94/00136

6

osteal materials to be used in surgery for sterile and biocompatibility promoting storage characterized in the embedding the endo-osteal material in an aqueous solution comprising an effective amount of a compound of formula (I)



wherein X is H, OH, Cl, F or a methyl group and Y is Cl, OH, $-(\text{CH}_2)_2-\text{N}(\text{CH}_3)-(\text{CH}_2)_4-\text{CH}_3$, $-(\text{CH}_2)_n-\text{CH}_3$ or $-(\text{CH}_2)_n-\text{NH}_2$, where
10 n is zero or an integer being 1 to 8, $-\text{NHZ}$, where Z is pyridinyl or cycloheptyl, SZ', where Z' is pyridinyl or chlorosubstituted phenyl or Y is a pyridinylsubstituted lower alkyl chain; or a non-toxic, pharmaceutically acceptable salt or ester thereof, after which the endo-
15 osteal material is either
- removed from the solution, dried and sterilized, or
- sealed in a vessel comprising a bisphosphonate solution and sterilized.

The invention concerns also the packaged endo-osteal
20 material to be used in surgery for sterile and biocompatibility promoting storage characterized in that said endo-osteal material treated with a solution of a bisphosphonate of the formula (I) or a non-toxic, pharmaceutically acceptable salt or ester thereof dissolved
25 in an appropriate solvent.

The term "endo-osteal material" shall be understood to include all kinds of endo-osteal prostheses and parts thereof to be introduced in the human body, e.g. artificial joints, hip prostheses, fixation plates for the skeleton
30 and implants, especially dental implants.

Particularly valuable members of formula (I) for the purpose of this invention are clodronate, where X and Y


WO 94/23770

PCT/FL94/00136

7

both are Cl; pamidronate, where X is OH and Y is
 -(CH₂)₂-NH₂; alendronic acid, where X is OH and Y is
 -(CH₂)₃-NH₂; neridronic acid, where X is OH and Y is
 -(CH₂)₅-NH₂; risedronic acid, where X is OH and Y is
 5 is 3-pyridinylmethyl; tiludronate, where X is H and Y is 4-
 chlorophenylthio; YM-175, where X is H and Y is
 cycloheptylamino; BM-210995, where X is OH and Y is
 -(CH₂)₂-N(CH₃)-(CH₂)₄-CH₃; and etidronate, where X is methyl
 and Y is OH. The most preferable compound for the purpose
 10 of the invention is clodronate or its pharmaceutically
 acceptable salts or esters.

The pharmaceutically acceptable salts and esters useful in
 the practice of this invention can be described by formula
 (II)



wherein X and Y are as defined above and M is hydrogen, a
 20 pharmaceutically acceptable cation, preferably an alkali
 metal cation such as sodium or potassium, or an alkyl or
 aryl moiety, e.g. an alkyl of 1 to 4 carbon atoms or
 phenyl.

The suitable amount of bisphosphonate to be added to the
 25 treatment solution ranges from 0.5 to 100 mg/ml, preferably
 1 to 10 mg/ml.

The treatment can be performed for example as follows:
 After manufacturing the endo-osteal prostheses they are
 embedded in a solution of 1 to 6 mg/ml of a bisphosphonate
 30 for a period ranging from about 20 minutes to 7 days. After
 that the endo-osteal prostheses can be dried and sterilized
 by gamma-radiation and stored in dry condition before their
 use. Alternatively the endo-osteal prostheses can be stored
 in the same or a similar bisphosphonate solution as that in

WO 94/23770

PCT/FD94/00136

8

which they were embedded. In this case the bisphosphonate solution is sterilized by gamma-radiation.

The treatment with bisphosphonates apply to endo-osteal prostheses having a ceramic surface as well as those having
5 no ceramic surface.

The inventive idea has been verified by animal and clinical tests. According to two separate studies with clodronate disodium, the methods and results of which are presented in
10 detail below, the effect of clodronate on bone tissue formation is demonstrated.

In the first test, the effect of clodronate on bone regeneration was tested in rabbit tibia. An experimental model involving free bone transplantation to the tibia was
15 developed. The tests revealed that clodronate had a positive effect on bone regeneration in the donor cavity and in the free bone grafts transplanted using a titanium screw. Clodronate-treated tibias were more quickly and more extensively vascularized than the control tibias.

20 The results of human studies, where the patients had an extra implant that was removed after a certain period of time, demonstrated that clodronate-medicated patients exhibited a more rapid bone formation than the unmedicated control group.

25 Hydroxyapatite and bisphosphonate molecules form a surface and not a chemical bond. In the surface there is a place for calcium atoms. Thus the calcium concentration is high. The composition of hydroxyapatite and bisphosphonate
30 forming a layer on the surface of the endo-osteal prosthesis or other implant is helpful in bone regeneration after surgery.

The effect of bisphosphonates for the treatment of implants has also been studied in tests reported below.

WO 94/23770

PCT/FI94/00136

9

Because of the close structural and pharmacological relationship between clodronate and its analogues as represented by formula (I) above it is justified to believe that the remaining members of formula (I) also are effective to promote the biocompatibility of endo-osteal prostheses including implants during their storage.

EXPERIMENTS

I. Effect of clodronate on bone regeneration in rabbits

The aim of the study was to determine whether clodronate had a positive effect on vascularization and bone formation in the tibia of a rabbit in which bone was transplanted with the aid of a titanium screw.

Materials and methods

Sixteen skeletally mature (3.5 - 3.9 kg) New Zealand white male rabbits were used. The animals were divided into two groups. Each group consisted of eight animals (16 tibiae). One group received clodronate disodium (Bonefos^R, Leiras Oy, Finland) 25 mg/kg i.m. twice a week. The other group (control) was untreated.

The rabbits were anaesthetized with an i.m. injection of 2.8 mg of Ketalar^R (Parke-Davis, Spain) and 2.0 ml of Rompun^R (Bayer, Germany).

The proximal ends of both tibiae were exposed and the periosteum removed from the operative area. A piece of cortical bone 4 mm across was removed using a trepan bur. A 0.6 mm titanium implant screw (Filpin, Filpol Dental, Ireland) was screwed through the piece. The piece, perforated with the implant, was screwed into place 3 mm above the donor cavity. Reference is made to Figure 1 representing the rabbit tibia, where A means the implant, T

WO 94/23770

PCT/FI94/00136

10

the transplant and F the donor cavity. The upper drawing of the Figure represents the cross section and the lower drawing the tibia as seen from above.

The animals were divided into two groups: microangiography was performed on eight animals and histological staining specimens was carried out from the other eighth animals. Roentgenological examinations with two steel wires with knots twisted around the tibiae to determine the exact positions of implant and donor cavity were performed. Reference is made to Figure 2, which discloses a lateral roentgen picture of tibia in the operation area. The letters A, T and F have the same meaning as in Figure 1.

Histological evaluation

Eight animals were killed for histological evaluations at various times after implantation: after 14 days (2 rabbits), 21 days (4 rabbits) and 35 days (2 rabbits). The number of control and clodronate-treated animals was the same each time.

Tibiae were fixed with 5 % phosphate-buffered formalin and toluidine blue staining and hematoxylin eosin (HE) were carried out. Specimens were inspected under a light microscope and adverse effects or signs of inflammation were recorded.

Microangiography

Eight animals (4 controls, 4 treated) were killed after 21 days by means of an i.v. dose of pentobarbital.

Before death the abdominal artery and vein were exposed and an 18-gauge angiocath was inserted and tied in place. A 20 ml syringe containing heparinized saline was used to infuse the abdominal artery. Infusion continued until a clear venous effluent emerged from the transacted abdominal

WO 94/23770

PCT/FI94/00136

11

veins. A 100 ml syringe filled with an orange-colored silicone rubber compound (Micro-Fil^R, Canton Biomedical, Boulder CO, USA) was then injected until orange effluent emerged from the abdominal veins. After the compound had
5 set for 4 hours, the tibiae were separated. The specimens were then sequentially dehydrated according to the cleaning technique of the manufacturer.

Using a scalpel, cross-sections were cut through the mid-portions of the grafts for viewing and slide photography
10 under a dissecting microscope. The absolute number of vessels penetrating the transplant host junction was counted by means of color transparencies (Eppley B et al., J Oral Maxillofac Surg. 1988; 46: 391-98).

The vessel count was performed in the specimen where the
15 most vessels were observed. Vessels were counted on two separate occasions by the same observers and the results were averaged. If the variation between two values was greater than 10 %, a third count was undertaken and the three counts were averaged. Vessel counts in both groups
20 were compared using a paired t-test; P values less than 0.05 were considered significant.

Results

The clinical observations revealed that all wounds healed uneventfully.

25 Evaluation of angiogenesis

When counting the vessels, most of them were clearly visible. It was, however, difficult to count the small vessels in the bone-transplant and bone-donor cavity junctions. Because of the variation in the two values by
30 the same observer the third count was undertaken in five specimens.

WO 94/23770

PCT/FI94/00136

12

Donor cavities

The number of vessels penetrating into the donor cavities was greater in rabbits treated with clodronate than for the control. The results are given in Table I below and the
5 difference is statistically significant ($P < 0.05$).

Table I

Number (x) of vessels penetrating donor cavity

	x	S.D.	Number of tibiae

10 Control	12.3	4.6	8
Clodronate treated	26.3	4.0	8

The difference in the amount of vessels can also be observed from the photographs of Figures 3 and 4. Figure 3 discloses a 21-day specimen from a rabbit treated with
15 clodronate. Implant and transplant are located in the centre of the picture. The donor cavity is seen to the right of the transplant. It can be seen that many vessels penetrate the donor cavity and transplant. Figure 4 shows a
21-day specimen from an untreated rabbit. Only a small
20 number of vessels penetrated the transplant.

Transplants

The transplants in the tibiae from the clodronate-treated animals became vascularized sooner and more extensively than in the tibiae from the control. The difference was
25 statistically significant ($P < 0.05$). The results are presented in Table II.

WO 94/23770

PCT/FI94/00136

13

Table II

Number (x) of vessels penetrating transplant

	x	S.D.	Number of tibiae

5 Control	4.75	1.7	8
Clodronate treated	13.0	4.0	8

The vessels penetrated closer to the centre of the cavity in the medicated rabbits than in the control group. In the medicated rabbits the number of vessels from one side of the specimen was greater than from the opposite side.

Histological findings

No signs of adverse tissue reactions or inflammation were observed when the specimens were studied under the light microscope.

15 Donor cavity

The 14-day control specimens exhibited slight collagen formation and were partly devoid of histologically visible elements in the middle part of the cavity. The clodronate-treated specimens exhibited more collagen formation than the control specimens. No empty spaces were seen. At three weeks, the control specimens exhibited only slight bone formation at the outer edges of the cavity. The inner part of the cavity was mainly filled with collagen and a sharp line between the cavity and bone was clearly seen. The clodronate-treated donor cavities were almost completely filled with new bone. Collagen was still found between new bone in the three-week specimens.

The five-week control cavities were partly filled with new bone, and the line between drilled cavity and bone was

WO 94/23770

PCT/FI94/00136

14

still seen in most parts of the cavity. The clodronate-treated cavities were completely filled with new bone and the drilling line was visible but the resolution between the donor cavity and old bone had started. Figure 5 illustrates a five-week control cavity. Bone regeneration is seen in middle of cavity and in drilling lines. The line between drilled cavity and bone is still seen in most parts of cavity. New bone formation with osteoblasts occurs occasionally in drilling line and also in centre of cavity. Figure 6 illustrates a five-week clodronate-treated cavity. Cavity is completely filled with new bone and drilling line is still visible but there is a fusion between donor cavity and cortical bone. Figures 7 and 8 represent greater magnifications of Figure 6. In Figure 7 solid new bone and osteoblasts can be observed. Figure 8 shows that cortical and new bone are almost completely fused.

Transplants

The soft tissue and periosteum above the transplants contained more collagen in the clodronate-treated group than in the control animals at all stages. Fourteen-day control specimens exhibited necrotic bone with invading collagen. Treated transplants were beginning to be resorbed at their outer edges. Figure 9 represents a side-view of four-week clodronate-treated rabbit's tibia. New bone covers transplant. Periosteum is intact but thinner than that above non-operated area. Implant and transplant are in the middle of this specimen. Donor cavity is to the right from transplant and is the reason for new bone formation in normally empty rabbit's spongy bone.

Twenty-one-day transplants were partly resorbed. New bone in the resorbed areas was seen in the treated tibiae. No bone formation was seen in control transplants. Bone formation around the implant in the cortical bone area was solid in the clodronate-treated group. Figure 10 represents

WO 94/23770

PCT/FI94/00136

15

a clodronate-treated 21-day specimen. Transplant is partly resorbed and replaced with new bone. The letters A and T represent implant and transplant, respectively, as in Figure 1, and E represents new bone adjacent to transplant and cortical tibia.

In 35-day specimens there was new bone formation almost throughout the transplants in the treated tibiae. Only solid bone was seen in the control transplants.

Regeneration of transplants occurs through microvascularization of the transplant. In a rat embryo study, Ray (Ray R D, Clin Orthop 1977; 87: 43-48) showed that vascularization of a rat embryo takes 3 to 4 weeks. In a review article, Burchardt (Burchardt H, Clin Orthop 1983; 174: 28-42) states that cancellous bone differs from cortical grafts as far as rates of revascularization are concerned. He suggested that revascularization of cancellous grafts can occur within hours as a result of end-to-end anastomoses from host vessels. Revascularization may be completed within two weeks (Ray R D; reference as above). A cortical graft is not penetrated by blood vessels until the sixth day (Ray R D; reference as above). Twenty-one days was selected on the basis of the results of a report by Eppley and co-workers (Eppley B et al., J Oral Maxillofac Surg 1988; 46: 391-98) as bone regeneration time after implantation. They found that the vascularization of bone grafts in rabbits reached a maximum after 21 days.

The results of the present study confirm the results of earlier reports (Bonjour J P; Ray R D; both references given above) as far as the control group is concerned. In the medicated rabbits vascularization occurred more quickly than in the control group. The histological findings show clearly that clodronate-treatment makes better bone. The results of the study suggests that bisphosphonates, particularly clodronate, are useful in implant and bone

WO 94/23770

PCT/FI94/00136

16

transplant patients where there is a high risk of failure of bone regeneration.

II. Human tests

Material and methods

5 The material of this study were 20 edentulous patients. They all came to the Institute of Dentistry, University of Turku, for an implantation procedure. The Institutional Review Board of the Faculty of Medicine at the University of Turku received the project in order to determine whether
10 human subjects are placed at risk. The unanimous decision made by the Institutional Review Board was that the human subjects concerned in this activity would not be placed at any risk. Patients gave permission for an explantation of an extra implant. 10 patients got a daily dose of 1600 mg
15 clodronate disodium until the extra implant was removed (the medicated group) and 10 patients got placebo. The medication and placebo administration, respectively, started one week before the surgery and continued for three weeks after the surgery.

20 Surgical technique

Routine method with five Astra implants was used. Fig. 11 is a front view human mandible with four Astra implants, where A means implants, E explanted implant with bone and N is the mandibular nerve. To avoid disturbances in neural
25 function implants are usually placed between the ends of mandibular nerve. At the operation an extra 4 mm screw was installed in the midline of the mandible.

Bone remodelling

At a separate operation the 4 mm extra implant was removed
30 with a trepan bore after 4 (10 patients, equally from both groups) and 12 weeks (10 patients, equally from both

WO 94/23770

PCT/FL94/00136

17

groups). The specimens were imbedded in acrylic blocks and divided in midline in two pieces. To the one piece a histological examination was performed. The other one was taken to a SEM-electromicroscopic examination.

- 5 Electromicroscopic examination in bone-implant interspace and bone in three points with SEM/EDXA (energy dispersive X-ray analysis) was made. At the four different places, two in the upper cortical bone, one in the middle of the implant and one in the bottom of that the following values
10 are calculated: sodium, calcium, phosphor, magnesium and titan. Calcium/phosphor and calcium/magnesium ratio were calculated in 12 points.

Results

Clinical treatment

- 15 All the wounds healed well. Two patients had problems with their lower denture under the healing period. They were treated by taking away a part denture. No side-effects were recorded. One patient had pain in his hip orthopedic prosthesis. Those disappeared after clodronate medication.

- 20 Histological examinations

One month-specimens

- Because all the mandibles were considerably resorbed and when the length of explanted implant was 4 mm biopsied bone was cortical in all specimens. The histological results are
25 shown in Figures 12 and 13, which both disclose the bone-implant specimen marked with E in Figure 11. Fig. 13 represents a greater magnification of Fig. 12. No spongy bone was seen. Soft gingival tissue covering the implants was healthy.

30

Histological examination revealed no more new bone in medicated than control-mandibles. There were no signs of

WO 94/23770

PCT/FL94/00136

18

inflammation. The space between implant and bone was mainly filled with collagen. In same points the contact between bone and implant was close. This is natural, because screwed Astra implants were used.

5 SEM-results

Table III shows the SEM results in human mandibles 4 weeks after implantation of an extra Astra implant. The 10 000 x SEM figure is the same as that Figures 11 and 12. The exact points where mineral concentrations are measured are shown with small numbers in Figure 14. The mean values of those standard points are given in Table III.

Table III

	CaO	P ₂ O ₅	CaO/P ₂ O ₅	Mg	Na
15 control	56	30	1.8	1.2	8.2
medicated	72	40	1.8	0.9	2.8

The values are given in weight percent.

Histological and SEM-pictures were similar in both groups. No differences under light and SEM-cross-over pictures were seen. In one month specimens P₂O₅ and CaO are both significantly greater in the medicated than in control mandibles. This means that rapid bone formation had begun, osteoclasts have resorbed bone. Osteogenesis is more intensive in medicated than in control patients.

III. Immersion studies

The effect of bisphosphonates for the treatment of implant surfaces before their use was verified in the following study. Twenty skeletally mature rabbits were used for the implantation of hydroxyapatite coated 6 mm IMZ-implants. Ten rabbits got 25 mg/kg i.m. clodronate in two injections

WO 94/23770

PCT/FI94/00136

19

one week before the surgery. Postoperative injections twice a week were continued for 18 days. The remaining ten rabbits did not get any systemic clodronate treatment before or after the surgery. In the operation an IMZ-
5 implant was implanted into both femurs of each rabbit. The implants operated into the right femurs of the rabbits had been immersed for five seconds in a physiological solution containing 6 mg/ml clodronate before the implantation. The implants operated into the left femurs of the rabbits were
10 not treated with clodronate before the implantation. The specimens were analysed according to methods described earlier. SEM examinations were carried out and the total amount of new bone (NB) as well as the amount of bone in contact with the implant (IB, i.e. osseointegration) was
15 determined.

All the wounds of the twenty rabbits healed without infections. Great variations in the NB and IB amounts were found. Preliminary results show that systemic clodronate treatment of the rabbits as well as immersion of the
20 implant in a clodronate solution before the implantation highly enhance the NB and IB formation. The highest NB and IB amounts were received where systemic clodronate treatment of the rabbits were combined with the immersion of the implant in a clodronate solution. Hydroxyapatite
25 coated IMZ implants immersed in a clodronate solution before the implantation into systemically medicated rabbits resulted in a more rapid bone remodelling than implantation of untreated IMZ implants to similarly systemically medicated rabbits.

30 Figure 15 shows an untreated implant operated into a nonmedicated rabbit. Figure 16 shows an immersed implant operated into a systemically medicated rabbit. The progress of the bone formation is clearly observed in Figure 16.


WO 94/23770

PCT/FI94/00136


20

CLAIMS

1. A method of treating endo-osteal materials to be used in surgery for sterile and biocompatibility promoting storage characterized in the embedding the endo-osteal material in an aqueous solution comprising an effective amount of a
- 5 bisphosphonate of the formula (I)



- wherein X is H, OH, Cl, F or a methyl group and Y is Cl,
- 10 OH, $-(\text{CH}_2)_2-\text{N}(\text{CH}_3)-(\text{CH}_2)_4-\text{CH}_3$, $-(\text{CH}_2)_n-\text{CH}_3$ or $-(\text{CH}_2)_n-\text{NH}_2$, where n is zero or an integer being 1 to 8, $-\text{NHZ}$, where Z is pyridinyl or cycloheptyl, SZ' , where Z' is pyridinyl or chlorosubstituted phenyl or Y is a pyridinylsubstituted lower alkyl chain; or a non-toxic, pharmaceutically
 - 15 acceptable salt or ester thereof, after which the endo-osteal material is either
 - removed from the solution, dried and sterilized, or
 - sealed in a vessel comprising a bisphosphonate solution and sterilized.
 - 20 2. A packaged endo-osteal material to be used in surgery for sterile and biocompatibility promoting storage characterized in that said endo-osteal material is treated with a solution of a bisphosphonate of the formula (I)



- wherein X is H, OH, Cl, F or a methyl group and Y is Cl,
- 30 OH, $-(\text{CH}_2)_2-\text{N}(\text{CH}_3)-(\text{CH}_2)_4-\text{CH}_3$, $-(\text{CH}_2)_n-\text{CH}_3$ or $-(\text{CH}_2)_n-\text{NH}_2$, where n is zero or an integer being 1 to 8, $-\text{NHZ}$, where Z is pyridinyl or cycloheptyl, SZ' , where Z' is pyridinyl or chlorosubstituted phenyl or Y is a pyridinylsubstituted

WO 94/23770

PCT/FI94/00136

21

lower alkyl chain; or a non-toxic, pharmaceutically acceptable salt or ester thereof dissolved in an appropriate solvent.

3. The packaged endo-osteal material according to claim 2
5 characterized in that said endo-osteal material is placed in a closed vessel comprising a sterilized solution of a bisphosphonate of the formula (I) or a non-toxic, pharmaceutically acceptable salt or ester thereof dissolved in an appropriate solvent.
- 10 4. The packaged endo-osteal material according to claim 2 or 3 characterized in that said endo-osteal material comprises a metal or metal alloy substrate.
5. The packaged endo-osteal material according to claim 4
15 characterized in that said endo-osteal material comprises a substrate of titanium or a titanium based alloy said substrate being coated with a bone-binding layer.
6. The packaged endo-osteal material according to claim 5 characterized in that said substrate is coated with a layer comprising hydroxyapatite.
- 20 7. A packaged endo-osteal material according to claim 2 or 3 characterized in that said endo-osteal material is a ceramic or glass-ceramic prosthesis.
8. A packaged endo-osteal material according to claim 2 or
3 characterized in that the bisphosphonate compound is
25 selected from the group consisting of clodronate, pamidronate, etidronate, alendronic acid, neridronic acid, risedronic acid, tiludronate, YM-175, BM-210995 and pharmaceutically acceptable salts and esters of said compounds.
- 30 9. The packaged endo-osteal material according to claim 8 characterized in that the compound is clodronate or its

WO 94/23770

PCT/FI94/00136

22

pharmaceutically acceptable salt or ester.

10. The packaged endo-osteal material according to claim 9 characterized in that the compound is clodronate disodium.

11. The packaged endo-osteal material according to claim 9
5 characterized in that the compound is clodronate disodium and the endo-osteal material is a dental implant comprising a substrate of titanium or a titanium based alloy said substrate being coated with a layer comprising hydroxyapatite.

WO 94/23770

PCT/FI94/00136




FIG. 1




FIG. 2

SUBSTITUTE SHEET

WO 94/23770

PCT/FI94/00136

2/13




FIG. 3




FIG. 4

WO 94/23770

PCT/FI94/00136

3/13




FIG. 5

WO 94/23770

PCT/FI94/00136

4/13




FIG. 6

WO 94/23770

PCT/FI94/00136

5/13




FIG. 7

WO 94/23770

PCT/F194/00136

6/13



FIG. 8

WO 94/23770

PCT/FI94/00136

7/13




FIG. 9




FIG. 10

WO 94/23770

PCT/FI94/00136

8/13




Fig. 11

WO 94/23770

PCT/FI94/00136

9/13




FIG. 12

WO 94/23770

PCT/FI94/00136

10/13




FIG. 13

WO 94/23770

PCT/FI94/00136

11/13



FIG. 14

WO 94/23770

PCT/FI94/00136

12/13




FIG. 15

SUBSTITUTE SHEET

WO 94/23770

PCT/FI94/00136

13/13




FIG. 16

1

INTERNATIONAL SEARCH REPORT

International application No.

PCT/FI 94/00136

A. CLASSIFICATION OF SUBJECT MATTER

IPC 5: A61L 27/00, A61L 2/16, B65B 55/12

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 5: A61L, B65B

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

WPI, CA, EPODOC

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US, A, 4763788 (LARS JÖRNEUS ET AL), 16 August 1988 (16.08.88) --	2,4-5
A	STN International, File CA, Chemical Abstract, volume 78, no. 25, 25 June 1973 (Columbus, Ohio, US) Jung, A et al: "Binding of pyrophosphate and two diphosphonates by hydroxylapatite crystals". abstract no. 155727, Calcif. Tissue Res. 1973 11 (4) 269-80 -----	1

☐ Further documents are listed in the continuation of Box C.☒ See patent family annex.

* Special categories of cited documents

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

4 July 1994

Date of mailing of the international search report

20 -07- 1994

Name and mailing address of the ISA/
Swedish Patent Office
Box 5055, S-102 42 STOCKHOLM
Facsimile No. +46 8 666 02 86

Authorized officer

Sofia Nikolopoulou
Telephone No. +46 8 782 25 00

Information on patent family members

International application No.

PCT/FI 94/00136

Form PCT/ISA/210 (patent family annex) (July 1992)